...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith - my take on TNBC and selling a royalty

Payzone, thanks for that post. Just an additional perspective, according to PharmaLetter, GlobalData's analyst concencus forecast for Trodelvy sales is $2.8B by 2028

Share
New Message
Please login to post a reply